USA: The results of the FOREMOST trial indicate that apremilast is effective for patients with early psoriatic arthritis (PsA ...

The mucocutaneous and articular clinical phenotype is the most common presentation of Behçet’s disease (BD).1 Current ...

With more than 300 patients in the trial, dubbed FOREMOST, 33.9% of those assigned to apremilast achieved minimal disease ...

Improvements in 2 patient-reported outcome measures were observed among patients with psoriasis treated with deucravacitinib vs placebo or apremilast.

NexoBrid Approval Expanded to Include Pediatric Burn Patients Otezla (apremilast) Phosphodiesterase type 4 inhibitor Treatment of pediatric patients 6 years of age and older weighing at least 20kg ...

Finding an effective treatment for psoriatic disease (PD) often requires trial and error. Because people experience PD differently, there's no one-size-fits-all ...

September 3, 2024 • A beloved beluga whale with a mysterious past was found dead in the waters of Norway over the weekend. Admirers are paying tribute as authorities investigate.

Since Sunday, Tropical Storm Enteng (international name: Yagi) has brought rains and caused heavy flooding in Metro Manila and its neighboring cities, with Signal No. 2 raised in nine areas in Luzon.

The Food and Drug Administration (FDA) has expanded the approval of apremilast and included treatment of children 6 years of age and older weighing at least 20kg with moderate to severe plaque ...

Apremilast is under clinical development by Amgen and currently in Phase II for Bullous Pemphigoid. According to GlobalData, Phase II drugs for Bullous Pemphigoid does not have sufficient historical ...

Study participants were randomly assigned to receive apremilast (n=163) or placebo (n=82) for 16 weeks. For the first time, children and adolescents with moderate to severe plaque psoriasis and their ...